NCT04123626: A reported trial by ProQR Therapeutics
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04123626 |
|---|---|
| Title | A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 7, 2019 |
| Completion date | June 7, 2022 |
| Required reporting date | June 7, 2023, midnight |
| Actual reporting date | Nov. 11, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 23, 2025 |
| Days late | None |